Here are Wednesday's biggest analyst calls: Nvidia, Tesla, Dell, First Solar, Affirm, Teva, Robinhood & more
Analysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
How this was made
The 30-second read
Why it matters
Overall, the piece provides a snapshot of analyst sentiment but lacks new primary corporate disclosures.
Market read
The roundup offers modest insight for traders seeking short-term moves on newly covered stocks.
What to watch
Potential for profit-taking on recent rallies; some ratings may be overly optimistic.
Background
The article compiles a list of analyst initiations, upgrades, and price target changes across various sectors.
Ticker impact
Loop initiates coverage of Affirm with a Buy rating and $105 price target.
Potential modest upside as investors price in new coverage.
Buy rating and high target suggest upside, but limited immediate catalyst.
StoneX initiates Robinhood Markets with a Buy rating and $170 price target.
Possible short-term rally.
Buy rating and target indicate positive outlook.
Loop initiates coverage of Chime Financial with a Buy rating and $45 price target.
Limited upside expected.
Small-cap fintech with modest target.
Loop initiates coverage of Dave Inc. with a Buy rating and $500 price target.
Potential significant upside if market reacts.
Aggressive target may drive speculative buying.
Piper Sandler initiates Quanta Services with an Overweight rating and $731 price target.
Modest upside expected.
Standard upgrade without major new catalyst.
UBS upgrades Thermo Fisher to Buy, expecting double-digit growth.
Potential modest price lift.
Upgrade aligns with existing growth expectations.
Morgan Stanley upgrades Lineage Logistics to Overweight, calling it a share gainer.
Limited upside.
Upgrade without new material news.
Piper Sandler initiates First Solar with an Overweight rating and $260 price target.
Potential modest upside.
Standard initiation.
Market effects
Broad analyst upgrades may slightly boost sentiment in tech and biotech sectors.
US market sentiment modestly positive due to multiple buy ratings.
Limited global impact; primarily US equity focus.
Counterpoint
Many upgrades may be priced in already; limited upside potential.
Key entities
- Analyst FirmLoop
Provides multiple buy initiations.
- Analyst FirmPiper Sandler
Issues upgrades and initiations.
